Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peg-interferon alfa, ribavirin, and rituximab combination therapy for HCV-related mixed cryoglobulinemia
2010-020659-30Phase 2Active
- Sponsor
- Policlinico di Bari
- Start
- Sep 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab, ribavirin and pegylated interferon alpha in cryoglobulinaemia, hepatitis C virus infection and chronic hepatitis, sponsored by Policlinico di Bari. Primary endpoints: Objective response rate and Complete response. Started Sep 2010; status: active.
02
Drugs
rituximabribavirinpegylated interferon alpha
03
Conditions
cryoglobulinaemiahepatitis C virus infectionchronic hepatitis
Beyond the preview
Go deeper on 2010-020659-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020659-30.